



challenges and future considerations for effective pharmacovigilance. *Expert Rev Neurother* 2013; 13: 251–261.

15. Rae-Grant A, Day SG, Marrie RA, Rabinstein A, Cree B, A Gronseth S, G.S, Haboubi M, Halperd J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebik S, Sitcov C, Sommers R, Stachowiak J, Getchius T, Shannon A, Merillat, Pringsheim T. Practice guideline recommendations summary: disease-modifying therapies for adults with sclerosis multiple sclerosis. *Neurology* 2018;90: 777–788.

16. Ortona E, Pierdominici M, Masseli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. *Ann Ist Super Sanita* 2016; 52: 205–212.

17. Shingo T, Gregg C, Enwere E, Fujikawa H, Hassam R, Geary C, Cross JC, Weiss S. Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin. *Science* 2003; 299: 117–120.

18. Tang MW, Garcia S, Gerlag DM, Tak PP, Reedquist KA. Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis. *Front Immunol* 2017; 8: 720.

19. Thöne J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy – safety considerations. *Expert Opin Drug Saf* 2017; 162: 523–534.

20. Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. *Mult Scler* 2013; 19: 15–23.

21. Voskuhl R, Momtazee C. Pregnancy: Effect on multiple sclerosis, treatment considerations, and breastfeeding. *Neurotherapeutics* (2017) 14: 974–984.

22. <http://www.olecich.cz/>